Clinical Guideline (CANMAT 2016) Discordance of Medications for Patients with Major Depressive Disorder in China

References

• Kato T, Furukawa TA, Mantani A, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder - The SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med. 2018;16(1):103.
   PubMedGoogle Scholar
• Leelahanaj T. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial. J Med Assoc Thai. 2012;95(5):S29–37.
   PubMedGoogle Scholar
• Wang Z, Gao K, Hong W, et al. Pharmacotherapy for acute mania and disconcordance with treatment guidelines: bipolar mania pathway survey (BIPAS) in mainland China. BMC Psychiatry. 2014;14(167):167.
   PubMedGoogle Scholar
• Wang Z, Gao K, Hong W, et al. Guidelines disconcordance in acute bipolar depression: data from the national Bipolar Mania Pathway Survey (BIPAS) in mainland China. PLoS One. 2014;9(4):e96096.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen J, Zhang C, et al. Guidelines concordance of maintenance treatment in euthymic patients with bipolar disorder: data from the national bipolar mania pathway survey (BIPAS) in mainland China. J Affect Disord. 2015;182:101–105.
   PubMed Web of Science ®Google Scholar
• Niu YJ. Interpretation of drug therapy of Chinese Guidelines for Prevention and Treatment of Depression. Clin Med J. 2018;16(5):6–8.
   Google Scholar
• Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001;46(1):38S–58S.
   PubMedGoogle Scholar
• Docherty M, Shaw K, Goulding L, et al. Evidence-based guideline implementation in low and middle income countries: lessons for mental health care. Int J Ment Health Syst. 2017;11:8.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540–560.
   PubMed Web of Science ®Google Scholar
• Tripathi AC, Upadhyay S, Paliwal S, Saraf SK. Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur J Med Chem. 2018;145:445–497.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2018;243:116–120.
   PubMed Web of Science ®Google Scholar
• Patel V, Xiao S, Chen H, et al. The magnitude of and health system responses to the mental health treatment gap in adults in India and China. Lancet. 2016;388(10063):3074–3084.
   PubMed Web of Science ®Google Scholar
• Zhang M. Major depressive disorder treatment guidelines in China. J Clin Psychiatry. 2010;71(Suppl E1):e06.
   PubMedGoogle Scholar
• Zhao D, Wu Z, Zhang H, et al. Somatic symptoms vary in major depressive disorder in China. Compr Psychiatry. 2018;87:32–37.
   PubMed Web of Science ®Google Scholar
• Chen YF. Chinese classification of mental disorders (CCMD-3): towards integration in international classification. Psychopathology. 2002;35(2–3):171–175.
   PubMed Web of Science ®Google Scholar
• Lee DT, Kleinman J, Kleinman A. Rethinking depression: an ethnographic study of the experiences of depression among Chinese. Harv Rev Psychiatry. 2007;15(1):1–8.
   PubMed Web of Science ®Google Scholar
• Parker G, Gladstone G, Chee KT. Depression in the planet’s largest ethnic group: the Chinese. Am J Psychiatry. 2001;158(6):857–864.
   PubMed Web of Science ®Google Scholar
• Singh A, Brooks MM, Voorhees RE, et al. Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression. Psychiatr Serv. 2017;68(1):81–87.
   PubMed Web of Science ®Google Scholar
• Zetterqvist AV, Mulinari S. Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation. PLoS One. 2013;8(5):e62609.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ji H, Niu Z, et al. Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder. Front Psychiatry. 2022;13:875141.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wu X, Liu H, et al. Employing biochemical biomarkers for building decision tree models to predict bipolar disorder from major depressive disorder. J Affect Disord. 2022;308:190–198.
   PubMed Web of Science ®Google Scholar
• Jaracz J, Gattner K, Jaracz K, Gorna K, Moczko J, Hauser J. Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression? Pharmacopsychiatry. 2018;51(4):148–152.
   PubMed Web of Science ®Google Scholar
• Mowla A, Dastgheib SA, RazeghianJahromi L. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: a Double-Blind, Randomized Controlled Trial. Clin Drug Investig. 2016;36(7):539–543.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li Y, Hu J, Zhong J, Population Pharmacokinetics LH. Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers. Eur J Drug MetabPharmacokinet. 2019;44(3):339–352.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhong Z, Hu J, et al. Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trial. BMC Psychiatry. 2015;15:84.
   PubMedGoogle Scholar
• Zhang Y, Becker T, Kosters M. Preliminary study of patterns of medication use for depression treatment in China. Asia Pac Psychiatry. 2013;5(4):231–236.
   PubMed Web of Science ®Google Scholar
• Solanki MS, Banwari G. Irrational fixed dose combinations of psychotropic drugs in India: cause of concern. Indian J Pharmacol. 2016;48(4):468–469.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wu Z, Sie O, et al. Causes of drug discontinuation in patients with major depressive disorder in China. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109755.
   PubMed Web of Science ®Google Scholar
• Cui L, Wang C, Wu Z, et al. Symptomatology differences of major depression in psychiatric versus general hospitals: a machine learning approach. J Affect Disord. 2020;260:349–360.
   PubMed Web of Science ®Google Scholar
• Huang CY, Yang SY, Mojtabai R, et al. Trends of Polypharmacy and Prescription Patterns of Antidepressants in Asia. J Clin Psychopharmacol. 2018;38(6):598–603.
   PubMed Web of Science ®Google Scholar
• Han C, Wang SM, Kato M, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851–870.
   PubMed Web of Science ®Google Scholar
• O’Brien H, Kiely F, Barry A, Meaney S. Cross-sectional examination of extrapyramidal side effects in a specialist palliative care inpatient unit. BMJ Support Palliat Care. 2018;9(3):271–273.
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Serretti A. Pharmacogenetics in Psychiatry. Adv Pharmacol. 2018;83:297–331.
   PubMedGoogle Scholar
• Zhu Y, Wu X, Zhou R, et al. Hypothalamic-Pituitary-End-Organ Axes: hormone Function in Female Patients with Major Depressive Disorder. Neurosci Bull. 2021;37(8):1176–1187.
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;8(12):CD008121.
   Google Scholar
• Qiu H, He Y, Zhang Y, et al. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Aust N Z J Psychiatry. 2018;52(12):1202–1212.
   PubMed Web of Science ®Google Scholar
• Xu Y. ‘Less is more’ in the Chinese context. Shanghai Arch Psychiatry. 2015;27(6):371–373.
   PubMedGoogle Scholar
• Karter AJ, Laiteerapong N, Chin MH, et al. Ethnic Differences in Geriatric Conditions and Diabetes Complications Among Older, Insured Adults With Diabetes: the Diabetes and Aging Study. J Aging Health. 2015;27(5):894–918.
   PubMed Web of Science ®Google Scholar
• Yang L, Su Y, Dong S, et al. Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China. Front Pharmacol. 2022;13:954973.
   PubMedGoogle Scholar
• Cazet L, Bulteau S, Evin A, et al. Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant? Expert Opin Drug MetabToxicol. 2018;14(8):879–886.
   PubMed Web of Science ®Google Scholar
• Yonemoto N, Tanaka S, Furukawa TA, et al. Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan. Trials. 2015;16:459.
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Yoshimura R, Harai H, et al. How many well vs. unwell days can you expect over 10 years, once you become depressed? Acta Psychiatr Scand. 2009;119(4):290–297.
   PubMed Web of Science ®Google Scholar
• Feng DD, Tang T, Lin XP, et al. Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review. Neuropsychiatr Dis Treat. 2016;12:2387–2402.
   PubMed Web of Science ®Google Scholar
• Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John’s wort) in depression: a meta-analysis. J Affect Disord. 2017;210:211–221.
   PubMed Web of Science ®Google Scholar
• Ravindran AV, Balneaves LG, Faulkner G, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: section 5. Complementary and Alternative Medicine Treatments. Can J Psychiatry. 2016;61(9):576–587.
   PubMed Web of Science ®Google Scholar
• Scheid V. Transmitting Chinese Medicine: changing Perceptions of Body, Pathology, and Treatment in Late Imperial China. Asian Med. 2013;8(2):299–360.
   Google Scholar